Somewhat Positive Media Coverage Somewhat Unlikely to Impact Smith & Nephew (NYSE:SNN) Share Price

News stories about Smith & Nephew (NYSE:SNN) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Smith & Nephew earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news stories about the medical equipment provider an impact score of 46.3109873660653 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of Smith & Nephew (SNN) traded down $0.69 during trading hours on Friday, hitting $35.82. 520,561 shares of the company were exchanged, compared to its average volume of 445,622. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.08 and a current ratio of 2.18. Smith & Nephew has a 1-year low of $29.76 and a 1-year high of $40.43.

A number of research analysts have issued reports on SNN shares. Morgan Stanley downgraded shares of Smith & Nephew from an “overweight” rating to an “equal weight” rating in a research report on Monday, December 11th. JPMorgan Chase & Co. upgraded shares of Smith & Nephew from a “neutral” rating to an “overweight” rating in a research report on Thursday, January 25th. Zacks Investment Research upgraded shares of Smith & Nephew from a “hold” rating to a “buy” rating and set a $43.00 price target on the stock in a research report on Wednesday, October 18th. Finally, Canaccord Genuity initiated coverage on shares of Smith & Nephew in a research report on Wednesday, October 11th. They issued a “buy” rating and a $42.00 price target on the stock. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $44.00.

WARNING: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at

Smith & Nephew Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Insider Buying and Selling by Quarter for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with's FREE daily email newsletter.

Leave a Reply